Strategic M&A Recent merger with Avere Therapeutics and asset sale to Xcellon Biologics indicate a period of corporate realignment and expanded manufacturing capability discussions. Potential sales angle: offer collaboration on early-stage programs or continuation of manufacturing services under the new CRDMO framework, targeting integrated discovery through clinical supply.

Expansion Opportunity Acquisition of SIM0505 license and a Move to become an end-to-end CRDMO with Xcellon suggests heightened demand for bioconjugate and complex biologics capabilities. Sales focus: present end-to-end CDMO services, analytical development, and GMP manufacturing packages to support ongoing and new immunomedicine programs.

Clinical Progress Positive ASCO data for SIM0505 dose escalation and FDA Fast Track designation for anti-CDH6 ADC underscore a pipeline with clinically relevant assets and regulatory momentum. Sales angle: provide strategic partnering discussions, CDMO support for GMP manufacturing, analytics, and regulatory readiness to accelerate timelines.

Financial Capacity Funding history including PIPE financing and a total funding runway of hundreds of millions, with current revenue in the tens of millions range. Business development leverage: position as a potential collaboration partner for co-development, manufacturing, or licensing opportunities to de-risk costs and accelerate value realization.

Global and Tech Readiness Operations supported by cloud and enterprise tech stack (AWS, Drupal, SharePoint, WordPress, Microsoft 365) indicate scalable digital infrastructure. Sales tactic: offer digital transformation, data management, and cloud-enabled collaboration solutions to streamline R&D operations and CRO/CDMO partnerships.